Difference between revisions of "Bivalirudin (Angiomax)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
m (Text replacement - "[[File:" to "[[:File:") |
||
| (3 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
==General information== | ==General information== | ||
| − | Class/mechanism: Direct thrombin inhibitor, binds reversibly to free and clot-associated thrombin at its catalytic site and anion-binding exosite and inhibits its effects of catalyzing the formation of fibrin from fibrinogen, platelet aggregation, activation of protein C, and activation of coagulation factors V, VIII, and XIII.<ref name="insert">[http://www.angiomax.com/downloads/ANG_USPI.pdf Bivalirudin (Angiomax) package insert]</ref><ref>[[ | + | Class/mechanism: Direct thrombin inhibitor, binds reversibly to free and clot-associated thrombin at its catalytic site and anion-binding exosite and inhibits its effects of catalyzing the formation of fibrin from fibrinogen, platelet aggregation, activation of protein C, and activation of coagulation factors V, VIII, and XIII.<ref name="insert">[http://www.angiomax.com/downloads/ANG_USPI.pdf Bivalirudin (Angiomax) package insert]</ref><ref>[[:File:Bivalirudin.pdf | Bivalirudin (Angiomax) package insert (locally hosted backup)]]</ref><ref>[http://www.angiomax.com/ Angiomax manufacturer's website]</ref> |
<br>Route: IV | <br>Route: IV | ||
<br>Extravasation: no information | <br>Extravasation: no information | ||
| Line 21: | Line 21: | ||
[[Category:Direct thrombin inhibitors]] | [[Category:Direct thrombin inhibitors]] | ||
| − | [[Category:Venous thromboembolism | + | [[Category:Venous thromboembolism medications]] |
| − | [[Category: | + | [[Category:FDA approved in 2000]] |
Latest revision as of 03:40, 20 September 2021
General information
Class/mechanism: Direct thrombin inhibitor, binds reversibly to free and clot-associated thrombin at its catalytic site and anion-binding exosite and inhibits its effects of catalyzing the formation of fibrin from fibrinogen, platelet aggregation, activation of protein C, and activation of coagulation factors V, VIII, and XIII.[1][2][3]
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Brief patient counseling information can be found in the Bivalirudin (Angiomax) package insert[1]
- Bivalirudin (Angiomax) patient drug information (UpToDate)[4]
Also known as
- Brand names: Angiomax, Angiox